Nyxoah SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 4, 2026, reports on Nyxoah SA, a Belgian company developing implantable treatments for sleep-disordered breathing. The filing primarily addresses a leadership transition, liquidity status, ongoing legal proceedings, and commercial progress in the U.S. and European markets.
Key Financial Metrics
- Cash and Liquidity: As of March 31, 2026, the Company held €25.9 million in cash, cash equivalents, and financial assets.
- Accumulated Deficit: €321.7 million as of March 31, 2026.
- Capital Raised: Total equity financing since inception is €332.5 million. Recent raises include €21.9 million in 2025, €69.7 million in 2024, and €18.9 million in 2023.
- Debt and Financing: The Company has an existing loan facility with the European Investment Bank (EIB) and an "at-the-market" (ATM) sales agreement with Cantor Fitzgerald allowing for up to $200.0 million in securities sales (including $50.0 million in ordinary shares).
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the current period.
Material Changes and Operational Updates
- Leadership Transition: On June 4, 2026, the Board launched a search for a new U.S.-based Chief Executive Officer to accelerate U.S. commercial traction. Current CEO Olivier Taelman will remain engaged during the transition.
- Commercial Growth (U.S.): In Q1 2026, active accounts increased by 60% quarter-over-quarter to 91. The commercial team now includes over 60 people, with 40 territory managers. Surgeon training reached 207 since August 2025.
- Commercial Growth (Germany): Achieved a 25% market share within 24 months of launch and 53% implant growth in 2025 compared to 2024.
- Clinical Data: Over 1,000 patients treated in Europe. The DREAM pivotal trial observed 82% of patients achieving an Apnea-Hypopnea Index (AHI) below 15 at 12 months.
- Collaboration Status: The collaboration agreement with Cochlear Limited is considered ended as all Statements of Work have been completed, though non-exclusive IP licenses remain.
Guidance, Risks, and Legal Proceedings
- Cash Runway: Based on the operating plan and existing cash as of December 31, 2025, plus the second tranche of the EIB loan, the cash runway is expected to extend into the third quarter of 2026.
- Legal Proceedings (Inspire Medical Systems):
- U.S. Litigation: Inspire sued Nyxoah in May 2025 alleging patent infringement. Nyxoah counter-sued in September 2025. On May 15, 2026, the Court consolidated these cases into a single proceeding.
- European Litigation: Nyxoah filed actions in the Unified Patent Court in Munich in December 2025 alleging Inspire infringes two European patents.
- Patent Review: Nyxoah's petitions for inter partes review of Inspire's asserted patents were denied institution by the USPTO on April 14, 2026.
- Risks: The Company highlights uncertainties regarding litigation outcomes, potential defense costs, and the reliance on forward-looking statements regarding market growth and FDA approval timelines.
Investor Verification Checklist
- Verify the timeline and criteria for the appointment of the new U.S.-based CEO.
- Confirm the exact date of the third quarter 2026 cash runway expiration and the status of the EIB loan tranche.
- Monitor the consolidated U.S. litigation schedule ordered by the Court for submission by June 18, 2026.
- Assess the impact of the denied inter partes review petitions on the Company's patent defense strategy.
- Review upcoming FDA approval timelines for the Genio system to validate the projected 15.8% market growth rate.